Bio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a report released on Wednesday. The firm set a “sell” rating on the stock.

Separately, Roth Mkm reissued a “buy” rating and set a $40.00 price objective on shares of Bio-Path in a report on Thursday, April 18th.

Bio-Path Trading Up 5.8 %

Shares of BPTH stock opened at $2.64 on Wednesday. Bio-Path has a 12 month low of $2.35 and a 12 month high of $44.80. The company has a market cap of $1.79 million, a P/E ratio of -0.06 and a beta of 0.35. The firm has a fifty day moving average price of $4.89 and a 200 day moving average price of $8.38.

Bio-Path (NASDAQ:BPTH) last released its quarterly earnings data on Friday, March 8th. The company reported ($5.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($5.40). During the same period last year, the firm earned ($10.60) EPS. On average, equities analysts forecast that Bio-Path will post -18.71 EPS for the current year.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.